News and Trends 1 Oct 2025 Asthma study suggests lung scarring may be reversible Find out about this new study that suggest that the lung scarring that severe asthma can cause could be reversible. October 1, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Reports Produced by Inpart 31 Jul 2025Immunology & inflammation R&D trends and breakthrough innovations Providing scientific decision-makers with a roadmap of high-impact I&I opportunities, emerging technologies, and potential future partners. July 31, 2025 Share WhatsApp Twitter Linkedin Email Produced by Inpart
In Depth 18 Jun 2025 From undruggable to oral therapy: The rise of STAT6 degraders Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment. June 18, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 2 May 2023 The future of asthma treatment: is a cure possible? For around 300 million people in the world, whipping out their inhaler – a medical device that delivers medicine to the lungs to open up narrowed airways – before puffing medicine into their mouth, is a typical response to wheezing, worsened by an asthma attack. While inhalers offer momentary relief, it is, however, no cure. […] May 2, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2023 Patients with asthma and other inflammatory lung diseases can be treated ‘in a fundamentally new way’ Arrowhead Pharmaceuticals Inc. has announced interim results from an ongoing phase 1/2 clinical study of ARO-RAGE, an investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for advanced glycation end products (RAGE) as a potential treatment for inflammatory pulmonary diseases, such as asthma. These data represent the first clinical demonstration of the […] April 27, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma Avillion LLP says the US Food and Drug Administration (FDA) has approved AstraZeneca’s Airsupra for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra, (albuterol/budesonide, formerly known as PT027) is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication […] January 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2022 Sanofi and Regeneron’s Dupixent shows sustained improvement in lung function in children A maintenance therapy from Sanofi and Regeneron, added to other asthma medications, has shown sustained improvement in lung function, low-rate of asthma attacks and a consistent safety profile for up to two years in children. Results from the longest global phase 3 open-label extension trial in the age group six to 11 years old with […] September 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Asthma in the spotlight as Upstream Bio starts trial and UK universities propose new long-term treatment Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, has initiated a phase 1b multiple ascending dose study of UPB-101 in asthma patients with the dosing of the first patient. Meanwhile, a possible way to tackle one of the underlying causes of asthma has been developed by researchers from Aston University and […] August 9, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 From mugwort allergy to an effective vaccine? A research team at MedUni Vienna in Austria says it has discovered key mechanisms of allergy to pollen from the common weed mugwort, which could lay the foundation for the development of the world’s first vaccine. Mugwort (Artemisia vulgaris) poses a serious problem for some people with allergies in places where the plant is common […] June 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2022 Upstream Bio to target asthma as it launches with $200M financing Upstream Bio, a U.S. biotech company focused on inflammation, today exited stealth mode with $200M Series A financing. The company said the funding will allow it to advance its lead program UPB-101, a clinical-stage monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. It added the investment will also help build a pipeline of assets […] June 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email